Home/Filings/3/0000899243-20-020225
3//SEC Filing

Third Rock Ventures III, L.P. 3

Accession 0000899243-20-020225

CIK 0001549595other

Filed

Jul 22, 8:00 PM ET

Accepted

Jul 23, 5:00 PM ET

Size

15.1 KB

Accession

0000899243-20-020225

Insider Transaction Report

Form 3
Period: 2020-07-23
Holdings
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (4,508,333 underlying)
  • Series D Preferred Stock

    Exercise: $0.00Common Stock (39,216 underlying)
  • Serries A-2 Preferred Stock

    Exercise: $0.00Common Stock (875,000 underlying)
Holdings
  • Serries A-2 Preferred Stock

    Exercise: $0.00Common Stock (875,000 underlying)
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (4,508,333 underlying)
  • Series D Preferred Stock

    Exercise: $0.00Common Stock (39,216 underlying)
LEVIN MARK J
10% Owner
Holdings
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (4,508,333 underlying)
  • Series D Preferred Stock

    Exercise: $0.00Common Stock (39,216 underlying)
  • Serries A-2 Preferred Stock

    Exercise: $0.00Common Stock (875,000 underlying)
STARR KEVIN P
10% Owner
Holdings
  • Serries A-2 Preferred Stock

    Exercise: $0.00Common Stock (875,000 underlying)
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (4,508,333 underlying)
  • Series D Preferred Stock

    Exercise: $0.00Common Stock (39,216 underlying)
Holdings
  • Serries A-2 Preferred Stock

    Exercise: $0.00Common Stock (875,000 underlying)
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (4,508,333 underlying)
  • Series D Preferred Stock

    Exercise: $0.00Common Stock (39,216 underlying)
Holdings
  • Serries A-2 Preferred Stock

    Exercise: $0.00Common Stock (875,000 underlying)
  • Series B Preferred Stock

    Exercise: $0.00Common Stock (4,508,333 underlying)
  • Series D Preferred Stock

    Exercise: $0.00Common Stock (39,216 underlying)
Footnotes (2)
  • [F1]Each share of the Issuer's Series A-2 Preferred Stock, Series B Preferred Stock and Series D Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
  • [F2]The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

Issuer

Nurix Therapeutics, Inc.

CIK 0001549595

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001569705

Filing Metadata

Form type
3
Filed
Jul 22, 8:00 PM ET
Accepted
Jul 23, 5:00 PM ET
Size
15.1 KB